Clinical Trial

Albuminuria Reduction Study With Survodutide Treatment in Kidney Disease

Study acronym: ARTIST-CKD
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The ARTIST-CKD trial is a clinical study evaluating the effect of weekly subcutaneous administration of survodutide (3.6 mg) on kidney function in patients with chronic kidney disease (CKD) and elevated albuminuria. The primary objective is to determine whether survodutide leads to early, sustained, and clinically meaningful reductions in albuminuria, regardless of diabetes status.
Trial Details
NCT Number NCT07206290
Lead Sponsor University Medical Center Groningen
Conditions Chronic Kidney Disease
Enrollment 120 participants
Start Date 2026-03-02
Primary Completion 2027-11-30 (estimated)
Study Completion 2027-11-30 (estimated)
Updated on ClinicalTrials.gov 2025-10-03